3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Multiple Myeloma
2
Melanoma
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
1
Neoplasms
1
Mouth Neoplasms
1
Lung Neoplasms
1
Laryngeal Diseases
1
Hodgkin Disease
1
Hepatoblastoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
pembrolizumab
24
Radiotherapy
21
Cisplatin
21
Cetuximab
13
Carboplatin
11
Paclitaxel
8
Nivolumab
8
durvalumab
7
Radiotherapy, Intensity-Modulated
6
Docetaxel
6
Fluorouracil
5
Cyclophosphamide
5
zalutumumab
4
Everolimus
4
Amifostine
4
spartalizumab
3
fludarabine
3
epacadostat
3
cemiplimab
3
Ipilimumab
3
Immune Checkpoint Inhibitors
3
Gefitinib
3
Filgrastim
3
Erlotinib Hydrochloride
3
Celecoxib
3
Capecitabine
3
selpercatinib
2
palbociclib
2
fludarabine phosphate
2
bintrafusp alfa protein, human
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Head and Neck Neoplasms
×
dostarlimab
×
Clear all
NCT05060432
2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2
Active not recruiting
153 enrolled